Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35163
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPurcell, Ruth A-
dc.contributor.authorAurelia, L Carissa-
dc.contributor.authorEsterbauer, Robyn-
dc.contributor.authorAllen, Lilith F-
dc.contributor.authorBond, Katherine A-
dc.contributor.authorWilliamson, Deborah A-
dc.contributor.authorTrevillyan, Janine M-
dc.contributor.authorTrubiano, Jason-
dc.contributor.authorJuno, Jennifer J-
dc.contributor.authorWheatley, Adam K-
dc.contributor.authorDavenport, Miles P-
dc.contributor.authorNguyen, Thi Ho-
dc.contributor.authorKedzierska, Katherine-
dc.contributor.authorKent, Stephen J-
dc.contributor.authorSelva, Kevin John-
dc.contributor.authorChung, Amy W-
dc.date2024-
dc.date.accessioned2024-03-27T05:08:58Z-
dc.date.available2024-03-27T05:08:58Z-
dc.date.issued2024-
dc.identifier.citationClinical & Translational Immunology 2024; 13(3)en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/35163-
dc.description.abstractAmino acid variations across more than 30 immunoglobulin (Ig) allotypes may introduce structural changes that influence recognition by anti-Ig detection reagents, consequently confounding interpretation of antibody responses, particularly in genetically diverse cohorts. Here, we assessed a panel of commercial monoclonal anti-IgG1 clones for capacity to universally recognise two dominant IgG1 haplotypes (G1m-1,3 and G1m1,17). Four commercial monoclonal anti-human IgG1 clones were assessed via ELISAs and multiplex bead-based assays for their ability to bind G1m-1,3 and G1m1,17 IgG1 variants. Detection antibodies were validated against monoclonal IgG1 allotype standards and tested for capacity to recognise antigen-specific plasma IgG1 from G1m-1,3 and G1m1,17 homozygous and heterozygous SARS-CoV-2 BNT162b2 vaccinated (n = 28) and COVID-19 convalescent (n = 44) individuals. An Fc-specific pan-IgG detection antibody corroborated differences between hinge- and Fc-specific anti-IgG1 responses. Hinge-specific anti-IgG1 clone 4E3 preferentially bound G1m1,17 compared to G1m-1,3 IgG1. Consequently, SARS-CoV-2 Spike-specific IgG1 levels detected in G1m1,17/G1m1,17 BNT162b2 vaccinees appeared 9- to 17-fold higher than in G1m-1,3/G1m-1,3 vaccinees. Fc-specific IgG1 and pan-IgG detection antibodies equivalently bound G1m-1,3 and G1m1,17 IgG1 variants, and detected comparable Spike-specific IgG1 levels between haplotypes. IgG1 responses against other human coronaviruses and influenza were similarly poorly detected by 4E3 anti-IgG1 in G1m-1,3/G1m-1,3 subjects. Anti-IgG1 clone 4E3 confounds assessment of antibody responses in clinical cohorts owing to bias towards detection of G1m1,17 IgG1 variants. Validation of anti-Ig clones should include evaluation of binding to relevant antibody variants, particularly as the role of immunogenetics upon humoral immunity is increasingly explored in diverse populations.en_US
dc.language.isoeng-
dc.subjectIgGen_US
dc.subjectallotypeen_US
dc.subjectanti‐immunoglobulinen_US
dc.subjectpolymorphismsen_US
dc.subjectreproducibilityen_US
dc.subjectserologyen_US
dc.titleImmunoglobulin G genetic variation can confound assessment of antibody levels via altered binding to detection reagents.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleClinical & Translational Immunologyen_US
dc.identifier.affiliationDepartment of Microbiology and Immunology The Peter Doherty Institute for Infection and Immunity, University of Melbourne Melbourne VIC Australia.en_US
dc.identifier.affiliationDepartment of Microbiology and Immunology The Peter Doherty Institute for Infection and Immunity, University of Melbourne Melbourne VIC Australia.en_US
dc.identifier.affiliationVictorian Infectious Diseases Reference Laboratory (VIDRL) The Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.;Walter and Eliza Hall Institute of Medical Research Parkville VIC Australia.;Department of Infectious Diseases The Peter Doherty Institute for Infection and Immunity, University of Melbourne Melbourne VIC Australia.en_US
dc.identifier.affiliationDepartment of Infectious Diseases The Peter Doherty Institute for Infection and Immunity, University of Melbourne Melbourne VIC Australia.;Centre for Antibiotic Allergy and Research, Department of Infectious Diseases Austin Health Heidelberg VIC Australia.en_US
dc.identifier.affiliationInfectious Diseasesen_US
dc.identifier.affiliationDepartment of Microbiology and Immunology The Peter Doherty Institute for Infection and Immunity, University of Melbourne Melbourne VIC Australia.en_US
dc.identifier.affiliationKirby Institute University of New South Wales Kensington NSW Australia.en_US
dc.identifier.doi10.1002/cti2.1494en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-6378-5114en_US
dc.identifier.orcid0000-0002-7091-0048en_US
dc.identifier.orcid0000-0002-9072-1017en_US
dc.identifier.orcid0000-0002-9294-7693en_US
dc.identifier.orcid0000-0001-6141-335Xen_US
dc.identifier.orcid0000-0002-8539-4891en_US
dc.identifier.orcid0000-0003-0020-9704en_US
dc.identifier.pubmedid38433763-
dc.description.volume13-
dc.description.issue3-
dc.description.startpagee1494-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptCentre for Antibiotic Allergy and Research-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on Oct 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.